Replimune Group (NASDAQ:REPL) Stock Price Down 6.4%

Replimune Group, Inc. (NASDAQ:REPL) shares dropped 6.4% on Monday . The company traded as low as $10.42 and last traded at $10.42. Approximately 206,275 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,123,318 shares. The stock had previously closed at $11.13.

Analysts Set New Price Targets

A number of research firms have recently issued reports on REPL. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research report on Monday. Barclays upped their target price on shares of Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Friday, June 7th. Wedbush reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Replimune Group in a research report on Thursday, June 6th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Replimune Group has an average rating of “Buy” and an average target price of $16.20.

Replimune Group Stock Down 5.8 %

The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $716.68 million, a price-to-earnings ratio of -3.44 and a beta of 1.22. The firm has a 50 day moving average price of $10.11 and a two-hundred day moving average price of $8.36.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.10. On average, equities analysts expect that Replimune Group, Inc. will post -3.08 earnings per share for the current fiscal year.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the transaction, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

A number of institutional investors have recently bought and sold shares of REPL. Nisa Investment Advisors LLC boosted its holdings in shares of Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the period. Point72 DIFC Ltd purchased a new position in Replimune Group during the 2nd quarter worth approximately $57,000. Quest Partners LLC acquired a new stake in Replimune Group during the 4th quarter valued at $76,000. Diversified Trust Co purchased a new stake in shares of Replimune Group in the first quarter valued at $94,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Replimune Group by 72.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock valued at $96,000 after buying an additional 4,975 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.